Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5946495 | 0.84 | TSHR (0.47) | TSHRMAPK1MAPTHSD17B10 | |
| SCHEMBL20262429 | 0.81 | TSHR (0.71) | TSHRALDH1A1SMN1; SMN2MAPK1GAA | |
| SCHEMBL26670065 | 0.81 | TSHR (0.64) | TSHRALDH1A1SMN1; SMN2MAPK1GAA | |
| SCHEMBL8194079 | 0.81 | TSHR (0.44) | TSHRTDP1 | |
| SCHEMBL298254 | 0.80 | TSHR (0.68) | TSHRALDH1A1SMN1; SMN2MAPK1GAA | |
| SCHEMBL5165163 | 0.79 | TSHR (0.40) | TSHR | |
| SCHEMBL24562 | 0.79 | TSHR (1.00) | TSHRALDH1A1SMN1; SMN2HPGDTDP1 | |
| SCHEMBL7678018 | 0.79 | TSHR (0.68) | TSHRALDH1A1SMN1; SMN2MAPK1GAA | |
| SCHEMBL6063406 | 0.79 | TSHR (0.68) | TSHRALDH1A1SMN1; SMN2MAPK1HPGD | |
| SCHEMBL13806617 | 0.78 | TSHR (0.41) | TSHRALDH1A1KDM4EMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112585113-B | Process for distillative purification of fluorine-containing polymerizable monomers | 中央硝子株式会社 | 2023-08-22 | — | — | CN | disclosed |
| US-11597696-B2 | Method for purifying polymerizable fluoromonomer by distillation | CENTRAL GLASS COMPANY, LIMITED (JP) | 2023-03-07 | — | — | US | disclosed |
| WO-2021231517-A1 | CURABLE OXAMATE ESTERS AND FORMULATIONS MADE THEREFROM | Henkel IP & Holding GmbH (DE) | 2021-11-18 | — | — | WO | disclosed |
| US-20210317065-A1 | Method for Purifying Polymerizable Fluoromonomer by Distillation | CENTRAL GLASS COMPANY, LIMITED (JP) | 2021-10-14 | — | — | US | disclosed |
| CN-112585113-A | Method for purifying fluorine-containing polymerizable monomer by distillation | 中央硝子株式会社 | 2021-03-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317065-A1 | Method for Purifying Polymerizable Fluoromonomer by Distillation | AFF1, AFF4, AFF2 | TSHR 3387/4885ALDH1A1 950/4885SMN1; SMN2 4320/4885 |
| US-11597696-B2 | Method for purifying polymerizable fluoromonomer by distillation | AFF1, AFF4, AFF2 | TSHR 3387/4885ALDH1A1 950/4885SMN1; SMN2 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.